Comparative Pharmacology
Head-to-head clinical analysis: BETIMOL versus TIMOLOL MALEATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETIMOL versus TIMOLOL MALEATE.
BETIMOL vs TIMOLOL MALEATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonselective beta-adrenergic receptor antagonist; reduces intraocular pressure by decreasing aqueous humor production.
Non-selective beta-adrenergic receptor antagonist (beta-blocker). Competitively blocks beta1 and beta2 receptors, reducing heart rate, myocardial contractility, and cardiac output. Also decreases aqueous humor production in the eye by blocking beta2 receptors on ciliary epithelium.
1 drop of 0.25% or 0.5% solution in the affected eye(s) twice daily. If inadequate response, increase to 0.5% solution twice daily.
Systemic: 1 drop of 0.25% or 0.5% solution in affected eye(s) twice daily. Additional indication: 0.5% gel-forming solution once daily. Oral: 10 mg twice daily, may increase to 20 mg twice daily if needed.
None Documented
None Documented
2.5 to 5 hours (average 4 hours) in patients with normal renal function; may be prolonged in renal impairment (up to 8-10 hours).
2-3 hours (terminal); prolonged in hepatic impairment
Primarily renal (unchanged drug and metabolites). Approximately 60-80% of a dose is excreted renally as unchanged timolol, with the remainder as inactive metabolites. Biliary/fecal excretion accounts for less than 20%.
Renal: 20% unchanged; biliary/fecal: 80% as metabolites
Category C
Category A/B
Beta-Blocker
Beta-Blocker